Vimarsana
Biggest News Aggregation in the World

Page 22 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

Vosoritide Approved for Achondroplasia in Children Under 5 Years by FDA - Vimarsana News

Vosoritide Approved for Achondroplasia in Children Under 5 Years by FDA

Children of all ages with achondroplasia are now included in the expanded Indication, the most common form of skeletal dysplasia leading to disproportionate short stature.

Source: ajmc.com
mCRC Treatment Sequencing Influenced By Combination Therapy - Vimarsana News

mCRC Treatment Sequencing Influenced By Combination Therapy

A recent FDA-approval is examined that provides new opportunities for effective combination strategies in mCRC treatment.

Source: ajmc.com
US FDA clears Santhera's improved steroid, Agamree, for DMD - Vimarsana News

US FDA clears Santhera's improved steroid, Agamree, for DMD

Less than two weeks after getting a thumbs-up from the EMA’s Committee for Medicinal Products for Human Use (CHMP), Santhera Pharmaceutical AG’s vamorolone secured U.S. FDA approval for use in patients, 2 and older, with Duchenne muscular dystrophy (DMD). A first-in-class drug, vamorolone, branded Agamree, is expected to offer a safer alternative to the steroid therapy, which the company has said will remain a foundational treatment of DMD, even with the introduction of gene therapies.

Coherus and Junshi Biosciences Announce FDA Approval of - Vimarsana News

Coherus and Junshi Biosciences Announce FDA Approval of

–  LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy...

FDA Approves Toripalimab for Recurrent or Metastatic Nasopharyngeal Carcinoma - Vimarsana News

FDA Approves Toripalimab for Recurrent or Metastatic Nasopharyngeal Carcinoma

The FDA has approved toripalimab-tpzi (Loqtorzi) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adult patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy.